• Akso Health Group launched proprietary brain-computer interface R&D program aimed at developing and commercializing next-generation neurotechnology.
• Program will build foundational R&D infrastructure to support development of BCI products.
• R&D focus includes ultra-high-resolution neural sensing, real-time AI neural decoding, interface design.
• Company plans to pursue patent protection for BCI innovations, with applications pending.
• Strategy targets use cases across neuroscience, advanced therapeutics, human-machine interaction, subject to R&D progress and regulatory processes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akso Health Group published the original content used to generate this news brief via PR Newswire (Ref. ID: CN43962) on April 27, 2026, and is solely responsible for the information contained therein.